|
Baseline cognitive function to predict survival in patients with glioblastoma. |
|
|
Consulting or Advisory Role - Novocure |
Research Funding - Agios; Eisai; Genentech; Merck; VBL Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech/Roche; Hospira; Pfizer |
Consulting or Advisory Role - Genentech/Roche; Hospira |
Speakers' Bureau - Genentech/Roche; Hospira; Pfizer |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Hospira; Pfizer |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Arno Therapeutics; Tactical Therapeutics |
Honoraria - Genentech/Roche |
Consulting or Advisory Role - Genentech/Roche |
Speakers' Bureau - Genentech/Roche |